# A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

> **NCT01509911** · PHASE2 · UNKNOWN · sponsor: **Tiltan Pharma Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** TL-118
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01509911
- **Lead sponsor:** Tiltan Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2016-10
- **Final completion:** 2017-01
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01509911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01509911, "A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01509911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*